Cargando…

Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis

OBJECTIVE: Little information is available about the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for patients with secondary myelofibrosis from essential thrombocythemia (ET) and polycythemia vera (PV). A nationwide retrospective study of the outcome of HSCT for post-ET and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murata, Makoto, Suzuki, Ritsuro, Nishida, Tetsuya, Shirane, Shuichi, Shimazu, Yutaka, Minami, Yosuke, Mori, Takehiko, Doki, Noriko, Kanda, Yoshinobu, Uchida, Naoyuki, Tanaka, Masatsugu, Ishikawa, Jun, Togitani, Kazuto, Fukuda, Takahiro, Ichinohe, Tatsuo, Atsuta, Yoshiko, Nagamura-Inoue, Tokiko, Kiyoi, Hitoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492130/ https://www.ncbi.nlm.nih.gov/pubmed/32801269 http://dx.doi.org/10.2169/internalmedicine.4375-19

Ejemplares similares

Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
por: Tefferi, A, et al.
Publicado: (2017)

The importance of cytogenetics in polycythemia vera, primary myelofibrosis and essential thrombocythemia
por: Conchon, Monika
Publicado: (2011)

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
por: Ogasawara, Ken, et al.
Publicado: (2019)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
por: Xu, Z., et al.
Publicado: (2022)

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
por: Barraco, Daniela, et al.
Publicado: (2018)

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
por: dos Santos, Leonardo Caires, et al.
Publicado: (2011)

Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial
por: Pardanani, A, et al.
Publicado: (2015)

Rapidly progressed aortic stenosis in a patient with previous diagnosis of polycythemia vera and post‐polycythemia vera myelofibrosis
por: Kiso, Shohei, et al.
Publicado: (2016)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

PB2211: DIFFERENCES IN POST-POLYCYTHEMIA VERA AND POST–ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS VS PRIMARY MYELOFIBROSIS IN FIBROTIC STAGE: A RETROSPECTIVE, REAL-WORLD STUDY CONDUCTED IN CHINA
por: Wang, Shengjie, et al.
Publicado: (2023)

P995: MYELOID NEOPLASMS-ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT
por: Mora, B., et al.
Publicado: (2022)

Updates in the management of polycythemia vera and essential thrombocythemia
por: Bose, Prithviraj, et al.
Publicado: (2019)

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
por: Barbui, T, et al.
Publicado: (2015)

Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
por: Agarwal, M. B., et al.
Publicado: (2015)

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
por: Pimpinelli, Fulvia, et al.
Publicado: (2021)

Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
por: Ishida, Hisashi, et al.
Publicado: (2020)

Emerging agents and regimens for polycythemia vera and essential thrombocythemia
por: Shallis, Rory M., et al.
Publicado: (2021)

Novel therapeutic strategies for essential thrombocythemia/polycythemia vera
por: Yoon, Seug Yun, et al.
Publicado: (2023)

Dermatomyositis Associated with Myelofibrosis following Polycythemia Vera
por: Fei, Naomi, et al.
Publicado: (2017)

An agenda for future research projects in polycythemia vera and essential thrombocythemia
por: Barbui, Tiziano, et al.
Publicado: (2020)

Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis
por: Koshiishi, Megumi, et al.
Publicado: (2017)

Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera
por: Pósfai, Éva, et al.
Publicado: (2016)

Cardiovascular Risk in Essential Thrombocythemia and Polycythemia Vera: Thrombotic Risk and Survival
por: Accurso, Vincenzo, et al.
Publicado: (2020)

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
por: Tefferi, A, et al.
Publicado: (2010)

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
por: Bryan, Jeffrey C., et al.
Publicado: (2016)

Progression of primary myelofibrosis to polycythemia vera: A case report
por: Guo, Yan, et al.
Publicado: (2017)

Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis
por: Song, Jinming, et al.
Publicado: (2017)

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
por: Dold, Leona, et al.
Publicado: (2021)

Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia
por: Sacco, Monica, et al.
Publicado: (2020)

Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study
por: Accurso, Vincenzo, et al.
Publicado: (2019)

Downregulated KLF2 in polycythemia vera and essential thrombocythemia induces prothrombotic gene expression
por: Song, Jihyun, et al.
Publicado: (2022)

The molecular profile in patients with polycythemia vera and essential thrombocythemia is dynamic and correlates with disease’s phenotype
por: Sobieralski, Patryk, et al.
Publicado: (2023)

Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000–2018
por: Mejía-Ochoa, Mónica, et al.
Publicado: (2019)

The Association Between Gene Polymorphisms and Leukocytosis with Thrombotic Complications in Patients with Essential Thrombocythemia and Polycythemia Vera
por: Mehtap, Özgür, et al.
Publicado: (2012)

Interferon alpha therapy in essential thrombocythemia and polycythemia vera - a systematic review and meta-analysis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2020)

Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia
por: Tremblay, Douglas, et al.
Publicado: (2021)

Pegylated Interferon Alpha-2b in Patients With Polycythemia Vera and Essential Thrombocythemia in the Real World
por: Sun, Yingxin, et al.
Publicado: (2021)

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera
por: Guglielmelli, Paola, et al.
Publicado: (2022)

Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
por: Podoltsev, Nikolai A., et al.
Publicado: (2023)

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
por: Ikeda, Kazuhiko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5digt9u7b81hdhapdjhf5bsrrg